Keywords: Allergan, Botox, Migraine, Regulators, Payers, Datamonitor
Approval of Allergan’s Botox for migraine “a headache for regulators and payers,” says Datamonitor
Article | 30 July 2010
Decisions from US and European regulators on the use of Allergan’s wrinkle reducer Botox (onabotulinumtoxin A) for the prophylactic treatment of chronic migraine are eagerly anticipated following UK approval this month (The Pharma Letter July 12). However, independent market analyst Datamonitor suggests that approval is far from guaranteed and assuming a positive outcome, reimbursement challenges will provide Allergan with an ongoing headache.
M Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
